No Picture
News

Heron Therapeutics Announces Financial Results for the Three and Six Months Ended  June 30, 2020 and Highlights Recent Corporate Updates

SAN DIEGO, Aug. 5, 2020 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best–in-class treatments to address some of the most important unmet p… […]

No Picture
News

Evofem Biosciences Reports Second Quarter 2020 Financial Results and Provides Corporate Update

– Advancing Precommercial Activities in Preparation for Phexxi(TM) Commercial Launch in September 2020 — Pivotal Phase 3 Trial of EVO100 for Prevention of Chlamydia and Gonorrhea on Track for Q4 2020 Initiation — Management to Host Conference Call Tu… […]

No Picture
News

Viking Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update

Conference call scheduled for 4:30 p.m. ET today- Enrollment Continues in Phase 2b VOYAGE Study of VK2809 in NASH; New Data from 12-Week Phase 2 Trial to be Highlighted at EASL- IND Filed for VK0214 in X-ALD; Phase 1 Trial Expected to Begin Q3 2020- Ba… […]

No Picture
News

DelMar Pharmaceuticals Announces Fiscal Third Quarter 2020 Financial Results and Recent Corporate Updates

SAN DIEGO, May 13, 2020 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announced its financial results for the thre… […]

No Picture
News

Halozyme Reports First Quarter 2020 Results

– DARZALEX FASPRO(TM) Utilizing ENHANZE® Technology Receives U.S. FDA Approval with Subcutaneous Administration Time of 3 – 5 Minutes and Lower Rate of Administration-related Reactions When Compared with IV DARZALEX® — Positive CHMP Opinion Recommendi… […]